{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:13:11Z","timestamp":1788883991252,"version":"build-2803163510"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP.2\/425\/46"],"award-info":[{"award-number":["RGP.2\/425\/46"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.colsurfb.2026.115589","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:31:10Z","timestamp":1772483470000},"page":"115589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Liposome-based nanocarriers for Ovarian cancer: Molecular targeting, therapeutic mechanisms, and clinical translation"],"prefix":"10.1016","volume":"263","author":[{"given":"Samar","family":"Raies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urushi","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrhman","family":"Alsayari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadma","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khang Wen","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-769X","authenticated-orcid":false,"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2026.115589_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e42188","article-title":"Extracellular vesicle miRNAs from three-dimensional ovarian cancer in vitro models and their implication in overall cancer survival","volume":"11","author":"Godbole","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.colsurfb.2026.115589_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2017.06.025","article-title":"Folic acid conjugated polymeric micelles loaded with a curcumin difluorinated analog for targeting cervical and ovarian cancers","volume":"157","author":"Luong","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2026.115589_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112766","article-title":"Polymeric nanoparticles-siRNA as an emerging nano-polyplexes against ovarian cancer","volume":"218","author":"Rehman","year":"2022","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2026.115589_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122894","article-title":"GLUT1 transporter-facilitated solid lipid nanoparticles loaded with anti-cancer therapeutics for ovarian cancer targeting","volume":"637","author":"Jagdale","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115589_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2024.12.017","article-title":"Multicenter study of ovarian cancer score for diagnosing ovarian cancer","volume":"193","author":"Wang","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2024.07.044","article-title":"Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population-based target trial emulation","volume":"232","author":"Jochum","year":"2025","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib7","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1002\/cam4.2560","article-title":"Ovarian cancer: Current status and strategies for improving therapeutic outcomes","volume":"8","author":"Chandra","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.colsurfb.2026.115589_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bspc.2024.107270","article-title":"Ovarian cancer diagnostics using wavelet packet scaling descriptors","volume":"102","author":"Hinton","year":"2025","journal-title":"Biomed. Signal Process. Control"},{"key":"10.1016\/j.colsurfb.2026.115589_bib9","article-title":"Treatment options for recurrent platinum-resistant ovarian cancer: A systematic review and Bayesian network meta-analysis based on RCTs","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2024.112800","article-title":"Carbon nanotube-mediated platinum-based drug delivery for the treatment of cancer: Advancements and future perspectives","volume":"206","author":"Sameer Khan","year":"2024","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.colsurfb.2026.115589_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2024.119933","article-title":"Engineering carbon-based nanomaterials for the delivery of platinum compounds: An innovative cancer disarming frontier","volume":"262","author":"Rahchamandi","year":"2024","journal-title":"Environ. Res."},{"key":"10.1016\/j.colsurfb.2026.115589_bib12","article-title":"Enhancing ovarian cancer treatment: Synergistic effects of methotrexate (Methotrexate)- and quercetin-loaded chitosan nanoparticles","volume":"8","author":"Dadashi","year":"2024","journal-title":"Carbohydr. Polym. Technol. Appl."},{"key":"10.1016\/j.colsurfb.2026.115589_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122899","article-title":"Nanoparticles in cancer theragnostic and drug delivery: a comprehensive review","volume":"352","author":"Al-Thani","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.colsurfb.2026.115589_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bmt.2023.09.001","article-title":"Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment","volume":"5","author":"Elumalai","year":"2024","journal-title":"Biomed. Technol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.pmatsci.2019.03.003","article-title":"Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging","volume":"103","author":"Kesharwani","year":"2019","journal-title":"Prog. Mater. Sci."},{"key":"10.1016\/j.colsurfb.2026.115589_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-023-01798-8","article-title":"Gold nanoparticles and gold nanorods in the landscape of cancer therapy","volume":"22","author":"Kesharwani","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.colsurfb.2026.115589_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.111837","article-title":"PAMAM dendrimer as a talented multifunctional biomimetic nanocarrier for cancer diagnosis and therapy","volume":"204","author":"Surekha","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2026.115589_bib18","article-title":"Formulation development and evaluation of rotigotine mucoadhesive nanoemulsion for intranasal delivery","volume":"54","author":"Choudhury","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib19","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1021\/acs.molpharmaceut.5b00827","article-title":"In Vivo Antitumor activity of folate-conjugated cholic acid-polyethylenimine micelles for the codelivery of doxorubicin and sirna to colorectal adenocarcinomas","volume":"12","author":"Amjad","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115589_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.112044","article-title":"Carbon nanotubes as an emerging nanocarrier for the delivery of doxorubicin for improved chemotherapy","volume":"208","author":"Chadar","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2026.115589_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2021.03.011","article-title":"The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer","author":"Singh","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.colsurfb.2026.115589_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jconrel.2021.08.003","article-title":"Advanced nanomedicine approaches applied for treatment of skin carcinoma","volume":"337","author":"Kaur","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2026.115589_bib23","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.3389\/fphar.2021.803304","article-title":"Recent progress of RGD modified liposomes as multistage rocket against cancer","volume":"12","author":"Sheikh","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib24","article-title":"Multivesicular liposome: a lipid-based drug delivery system for efficient drug delivery","volume":"27","author":"A.-D. BE","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.colsurfb.2026.115589_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2022.111781","article-title":"Immunoliposomes as an emerging nanocarrier for breast cancer therapy","volume":"184","author":"Parveen","year":"2023","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.colsurfb.2026.115589_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103819","article-title":"Unravelling the potential of mitochondria-targeted liposomes for enhanced cancer treatment","volume":"29","author":"Khan","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.colsurfb.2026.115589_bib27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/bs.pmbts.2023.12.010","article-title":"Advances in liposome-based delivery of RNA therapeutics for cancer treatment","volume":"204","author":"Sanati","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.colsurfb.2026.115589_bib28","article-title":"Ellagic acid nanoliposomes potentiate therapeutic effects of PEGylated liposomal doxorubicin in melanoma: An in vitro and in vivo study","volume":"93","author":"Heidarian","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib29","first-page":"400","article-title":"Liposome-Based Drug Delivery Systems in Cancer Research: An Analysis of Global Landscape Efforts and Achievements","volume":"16","author":"Hamad","year":"2024","journal-title":"Pharm"},{"key":"10.1016\/j.colsurfb.2026.115589_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2022.12.013","article-title":"Liposome-based diagnostic and therapeutic applications for pancreatic cancer","volume":"157","author":"Raza","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.colsurfb.2026.115589_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/bmm2.12083","article-title":"Rational design of a nonclassical liposomal nanoscale drug delivery system for innovative cancer therapy","volume":"2","author":"Wang","year":"2024","journal-title":"BMEMat"},{"key":"10.1016\/j.colsurfb.2026.115589_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00404-013-3114-3","article-title":"The heterogeneity of ovarian cancer","volume":"289","author":"Meinhold-Heerlein","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.colsurfb.2026.115589_bib33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025589","article-title":"Theranostic nanostructures for ovarian cancer","volume":"36","author":"Navyatha","year":"2019","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"10.1016\/j.colsurfb.2026.115589_bib34","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.AOG.0000220516.34053.48","article-title":"Diagnosis and management of epithelial ovarian cancer","volume":"107","author":"Bhoola","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/gyno.1997.4737","article-title":"Age at onset of ovarian cancer in women with a strong family history of ovarian cancer","volume":"66","author":"Goldberg","year":"1997","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib37","doi-asserted-by":"crossref","first-page":"e23056","DOI":"10.1096\/fj.202202103R","article-title":"Identification of the hub genes in polycystic ovary syndrome based on disease-associated molecule network","volume":"37","author":"Wu","year":"2023","journal-title":"FASEB J."},{"key":"10.1016\/j.colsurfb.2026.115589_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.23736\/S0026-4806.19.06091-9","article-title":"Hereditary ovarian cancers: state of the art","volume":"110","author":"Toss","year":"2019","journal-title":"Minerva Med"},{"key":"10.1016\/j.colsurfb.2026.115589_bib39","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1136\/ijgc-2020-001556","article-title":"Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes","volume":"30","author":"Pietragalla","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.colsurfb.2026.115589_bib40","doi-asserted-by":"crossref","first-page":"12372","DOI":"10.1073\/pnas.1109363108","article-title":"Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer","volume":"108","author":"Cheung","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.colsurfb.2026.115589_bib41","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1124\/jpet.118.254979","article-title":"Nanotechnology and immunotherapy in ovarian cancer: Tracing new landscapes","volume":"370","author":"Corradetti","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.colsurfb.2026.115589_bib42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jjco\/hyaa015","article-title":"Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer","volume":"50","author":"Nishio","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib43","first-page":"111","article-title":"Surgical Debulking of Ovarian Cancer: What Difference Does It Make?","volume":"3","author":"Schorge","year":"2010","journal-title":"Rev. Obstet. Gynecol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib44","unstructured":"n.d., Recommendation of the Polish Society of Oncological Gynaecology on the diagnosis and treatment of epithelial ovarian cancerBasta | Oncology in Clinical Practicehttps:\/\/journals.viamedica.pl\/oncology_in_clinical_practice\/article\/view\/44800\/36018(accessed July 21, 2022).."},{"key":"10.1016\/j.colsurfb.2026.115589_bib45","doi-asserted-by":"crossref","first-page":"viii36","DOI":"10.1093\/annonc\/mdx450","article-title":"Front-line therapy of advanced epithelial ovarian cancer: standard treatment","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib46","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet (Lond. Engl. )"},{"key":"10.1016\/j.colsurfb.2026.115589_bib47","first-page":"96","article-title":"Taxanes, microtubules and chemoresistant breast cancer","volume":"1785","author":"McGrogan","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.colsurfb.2026.115589_bib48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/IJWH.S52379","article-title":"New perspectives on targeted therapy in ovarian cancer","volume":"7","author":"Coward","year":"2015","journal-title":"Int. J. Women\u2019s. Health"},{"key":"10.1016\/j.colsurfb.2026.115589_bib49","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.2217\/nnm-2018-0379","article-title":"Nanoparticle-siRNA: A potential strategy for ovarian cancer therapy?","volume":"14","author":"Aghamiri","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.colsurfb.2026.115589_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2015.03.001","article-title":"Prediction of drug-ABC-transporter interaction--Recent advances and future challenges","volume":"86","author":"Montanari","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2026.115589_bib51","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0090-8258(03)00073-8","article-title":"Palliative surgery for bowel obstruction in recurrent ovarian cancer:an updated series","volume":"89","author":"Pothuri","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.colsurfb.2026.115589_bib52","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0360-3016(92)90777-F","article-title":"Epithelial ovarian cancer: the role of radiotherapy","volume":"22","author":"Dembo","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.colsurfb.2026.115589_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fonc.2017.00177","article-title":"Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future","volume":"7","author":"Fields","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib54","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/156720107782151269","article-title":"Liposomal Drug Delivery Systems: An Update Review","volume":"4","author":"Samad","year":"2007","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.colsurfb.2026.115589_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117460","article-title":"A review on tumor-targeting liposomes: Fabrication, mechanism and applications","volume":"243","author":"Basak","year":"2026","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/s12958-023-01125-2","article-title":"Liposomal delivery of gene therapy for ovarian cancer: a systematic review","volume":"21","author":"Son","year":"2023","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bmt.2023.09.001","article-title":"Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment","volume":"5","author":"Elumalai","year":"2024","journal-title":"Biomed. Technol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.783831","article-title":"A Review on Polymer and Lipid-Based Nanocarriers and Its Application to Nano-Pharmaceutical and Food-Based Systems","volume":"8","author":"Lu","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.colsurfb.2026.115589_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/nano12081376","article-title":"Nanocarriers for Drug Delivery: An Overview with Emphasis on Vitamin D and K Transportation","volume":"12","author":"Crintea","year":"2022","journal-title":"Nanomater"},{"key":"10.1016\/j.colsurfb.2026.115589_bib60","doi-asserted-by":"crossref","unstructured":"n.d., Cancer nanomedicine: a review of nano-therapeutics and challenges aheadRSC AdvancesRSC Publishinghttps:\/\/pubs.rsc.org\/en\/content\/articlehtml\/2023\/ra\/d2ra07863e?utm_source=chatgpt.com(accessed January 17, 2026). DOI:10.1039\/D2RA07863E.","DOI":"10.1039\/D2RA07863E"},{"key":"10.1016\/j.colsurfb.2026.115589_bib61","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/pharmaceutics12111054","article-title":"Liposome-Based Drug Delivery Systems in Cancer Immunotherapy","volume":"12","author":"Gu","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2026.115589_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114304","article-title":"A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer","volume":"160","author":"Xie","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.colsurfb.2026.115589_bib63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/17458080.2021.1922669","article-title":"Investigation of characterization and cytotoxic effect of PEGylated nanoliposomal containing Melphalan on ovarian cancer: an in vitro study","volume":"16","author":"Mirnezami","year":"2021","journal-title":"J. Exp. Nanosci."},{"key":"10.1016\/j.colsurfb.2026.115589_bib64","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3390\/cancers14122868","article-title":"An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment","volume":"14","author":"Sharifi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.colsurfb.2026.115589_bib65","first-page":"2023","article-title":"Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors","volume":"Vol. 24","author":"Kim","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2026.115589_bib66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor Targeting via EPR: Strategies to Enhance Patient Responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2026.115589_bib67","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.7150\/thno.37198","article-title":"Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment","volume":"9","author":"Park","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.colsurfb.2026.115589_bib68","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.colsurfb.2026.115589_bib69","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/cancers12061647","article-title":"Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer","volume":"12","author":"Langdon","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.colsurfb.2026.115589_bib70","unstructured":"S. Cunat, P. Hoffmann, P. PujolEstrogens and epithelial ovarian cancer 10.1016\/j.ygyno.2004.03.0262004."},{"key":"10.1016\/j.colsurfb.2026.115589_bib71","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2147\/IJN.S362263","article-title":"Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs","volume":"17","author":"Tang","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2026.115589_bib72","first-page":"3051","article-title":"Expression and Function of CD44 in Epithelial Ovarian Carcinoma","volume":"5","author":"Sacks","year":"2015","journal-title":"Biomol"},{"key":"10.1016\/j.colsurfb.2026.115589_bib73","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.2147\/IJN.S455942","article-title":"Construction of ROS-Responsive Hyaluronic Acid Modified Paclitaxel and Diosgenin Liposomes and Study on Synergistic Enhancement of Anti-Ovarian Cancer Efficacy","volume":"19","author":"Tang","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2026.115589_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12645-023-00236-0","article-title":"CD44-specific short peptide A6 boosts cellular uptake and anticancer efficacy of PEGylated liposomal doxorubicin in vitro and in vivo","volume":"14","author":"Yazdian-Robati","year":"2023","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib75","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/414676","article-title":"Targeting the EGF Receptor for Ovarian Cancer Therapy","volume":"2010","author":"Zeineldin","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib76","first-page":"1","article-title":"Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy","volume":"11","author":"Lin","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.colsurfb.2026.115589_bib77","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.colsurfb.2026.115589_bib78","first-page":"350","article-title":"Two drugs are better than one. A short history of combined therapy of ovarian cancer","volume":"19","author":"Bukowska","year":"2014","journal-title":"Contemp. Oncol. Onkol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib79","unstructured":"M. Bahrami Parsa, F. Tafvizi, V. Chaleshi, M. EbadiPreparation, characterization, and Co-delivery of cisplatin and doxorubicin-loaded liposomes to enhance anticancer Activities 9 Heliyon2023, 2405844010.1016\/J.HELIYON.2023.E20657\/ATTACHMENT\/4BA4D15B-2202-4DA7-B4F6-E8D1E5DD8787\/MMC1.DOCX."},{"key":"10.1016\/j.colsurfb.2026.115589_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-024-03469-0","article-title":"Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells","volume":"24","author":"Romaniuk-Drapala","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.colsurfb.2026.115589_bib81","article-title":"Methotrexate-modified docetaxel liposome targeting with ginsenoside Rh2 as a membrane stabilizer for the treatment of ovarian cancer","volume":"98","author":"Liu","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib82","unstructured":"J. Li, Y. Wang, Y. Zhu, D. Oupick\u00fdRecent Advances in Delivery of Drug-Nucleic Acid Combinations for Cancer Treatment 10.1016\/j.jconrel.2013.04.0102013."},{"key":"10.1016\/j.colsurfb.2026.115589_bib83","article-title":"A folic acid-modified non-viral vector combines gene therapy with chemotherapy to reverse cancer chemotherapy resistance","volume":"26","author":"Chen","year":"2022","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.colsurfb.2026.115589_bib84","first-page":"1","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer 2024 231"},{"key":"10.1016\/j.colsurfb.2026.115589_bib85","first-page":"1","article-title":"Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer","volume":"20","author":"Li","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib86","doi-asserted-by":"crossref","first-page":"11669","DOI":"10.1021\/acsomega.1c00992","article-title":"Liposomal delivery of MicroRNA-7 targeting EGFR to inhibit the growth, invasion, and migration of Ovarian cancer","volume":"6","author":"Cui","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.colsurfb.2026.115589_bib87","unstructured":"J.Gu Cho, D. Lim, Y. Do, B. Su Kwon, W. Chang, M.-S. Lee, J. Kim, n.d., BMB Reports *Corresponding authorsAngiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer 10.5483\/BMBRep.2020.53.6.060."},{"key":"10.1016\/j.colsurfb.2026.115589_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120013","article-title":"The anti-ovarian cancer effect of RPV modified paclitaxel plus schisandra B liposomes in SK-OV-3 cells and tumor-bearing mice","volume":"285","author":"Zhang","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.colsurfb.2026.115589_bib89","article-title":"Octreotide modified liposomes that co-deliver paclitaxel and neferine effectively inhibit ovarian cancer metastasis by specifically binding to the SSTR2 receptors","volume":"98","author":"Liu","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib90","doi-asserted-by":"crossref","first-page":"a008797","DOI":"10.1101\/cshperspect.a008797","article-title":"The role of apoptosis-induced proliferation for regeneration and cancer","volume":"4","author":"Ryoo","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112000","article-title":"Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer","volume":"142","author":"Faria","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.colsurfb.2026.115589_bib92","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2147\/IJN.S266676","article-title":"Externally triggered novel rapid-release sonosensitive folate-modified liposomes for gemcitabine: development and characteristics","volume":"16","author":"Omar","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2026.115589_bib93","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jconrel.2024.05.005","article-title":"HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model","volume":"371","author":"Juul","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2026.115589_bib94","unstructured":"S. Ramishetti, L. HuangIntelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy 10.4155\/tde.12.1272012."},{"key":"10.1016\/j.colsurfb.2026.115589_bib95","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2147\/IJN.S285950","article-title":"Lipoparticles for synergistic chemo-photodynamic therapy to ovarian carcinoma cells: in vitro and in vivo assessments","volume":"16","author":"Ali","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2026.115589_bib96","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pdpdt.2011.08.003","article-title":"Photodiagnosis and photodynamic therapy of peritoneal metastasis of ovarian cancer","volume":"9","author":"Guyon","year":"2012","journal-title":"Photo Photodyn. Ther."},{"key":"10.1016\/j.colsurfb.2026.115589_bib97","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejpb.2023.11.008","article-title":"HER2-specific liposomes loaded with proteinaceous BRET pair as a promising tool for targeted self-excited photodynamic therapy","volume":"193","author":"Shramova","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2026.115589_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e13823","article-title":"PEGylated liposomes enhance the effect of cytotoxic drug: a review","volume":"9","author":"Taher","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.colsurfb.2026.115589_bib99","doi-asserted-by":"crossref","first-page":"22122","DOI":"10.1021\/acsnano.4c05409","article-title":"Liposomes with low levels of grafted poly(ethylene glycol) remain susceptible to destabilization by anti-poly(ethylene glycol) antibodies","volume":"18","author":"Chen","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.colsurfb.2026.115589_bib100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/ctrv.2002.0262","article-title":"Pegylated liposomal doxorubicin (Caelyx\u2122) in recurrent ovarian cancer","volume":"28","author":"Stebbing","year":"2002","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.colsurfb.2026.115589_bib101","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/ejhpharm-2020-002311","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: a literature review of pharmaceutical and clinical aspects","volume":"28","author":"Zhu","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115589_bib102","unstructured":"n.d., Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer - PubMedhttps:\/\/pubmed.ncbi.nlm.nih.gov\/20332467\/(accessed January 17, 2026).."},{"key":"10.1016\/j.colsurfb.2026.115589_bib103","unstructured":"n.d., Caelyx pegylated liposomal | European Medicines Agency (EMA)https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/caelyx-pegylated-liposomal?utm_source=chatgpt.com(accessed January 17, 2026).."},{"key":"10.1016\/j.colsurfb.2026.115589_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00790","article-title":"Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization","volume":"9","author":"Hua","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib105","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.colsurfb.2026.115589_bib106","doi-asserted-by":"crossref","first-page":"12003","DOI":"10.1080\/21655979.2021.2002494","article-title":"Rhophilin rho GTPase binding protein 1-antisense RNA 1 (RHPN1-AS1) promotes ovarian carcinogenesis by sponging microRNA-485-5p and releasing DNA topoisomerase II alpha (TOP2A)","volume":"12","author":"Zhou","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.colsurfb.2026.115589_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/app15063189","article-title":"Enhancement of EPR effect for passive tumor targeting: current status and future perspectives","volume":"15","author":"Vagena","year":"2025","journal-title":"Appl. Sci."},{"key":"10.1016\/j.colsurfb.2026.115589_bib108","article-title":"Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management \u2013 a comprehensive review","volume":"15","author":"Kumar","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib109","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.colsurfb.2026.115589_bib110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","article-title":"Smart nanoparticles for cancer therapy","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:16:49Z","timestamp":1778775409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776526001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":110,"alternative-id":["S0927776526001773"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115589","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposome-based nanocarriers for Ovarian cancer: Molecular targeting, therapeutic mechanisms, and clinical translation","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115589"}}